Tekin Fatih, Koksal Deniz, Dikmen Z Gunnur, Karahan Sevilay, Bayler Rıdvan, Ancın Burcu, Dikmen Erkan, Akinci Devrim, Onder Sevgen
Department of Chest Diseases, Hacettepe University Medical Faculty, Ankara, Turkey.
Mesothelioma and Medical Geology Application and Research Center, Hacettepe University, Ankara, Turkey.
Cancer Biomark. 2025 Jan;42(1):18758592241293231. doi: 10.1177/18758592241293231. Epub 2025 Mar 20.
Malignant pleural effusion (MPE) is a common clinical problem. Management options are mainly pleurodesis and drainage, and have remained unchanged for years. Novel therapies that target the molecules responsible for fluid formation are needed to reduce the need for invasive procedures. The aim of this study is to investigate the potential role of MCP-1 in the development of MPE in patients with metastatic pleural malignancies. Pleural effusion samples (8-10 ml) were collected from 100 patients who were divided into three groups: Group 1 (MPE, n = 56), Group 2 (benign exudate, n = 27) and Group 3 (transudate, n = 17). The collected effusions were promptly centrifuged at 4°C, and the supernatants were stored at -80°C. MCP-1 levels were determined by ELISA kit (USCN, Wuhan). Median MCP-1 levels were found to be significantly different between the three groups (Group 1: 1303 pg/ml, Group 2: 926 pg/ml, Group 3: 211 pg/ml) ( < 0.001). MCP-1 levels were markedly higher but similar in Group 1 and Group 2, as compared to Group 3. When patients from Group 1 and Group 2 were combined, a positive correlation was observed between pleural fluid MCP-1 and LDH levels (r = 0.38; = 0.001). Additionally, MCP-1 levels were observed to increase significantly as the volume of pleural fluid increased ( = 0.007). MCP-1 levels were found to be similarly high in both Group 1 (MPE) and Group 2 (Benign exudate), indicating that inflammation accompanying the tumor could play a role in the formation of pleural effusion. This suggests that the development of biological therapies targeting MCP-1 could be a promising approach in the future management of MPE.
恶性胸腔积液（MPE）是一个常见的临床问题。治疗方案主要是胸膜固定术和引流，多年来一直未变。需要针对负责液体形成的分子的新型疗法，以减少侵入性操作的需求。本研究的目的是调查MCP-1在转移性胸膜恶性肿瘤患者MPE发生中的潜在作用。从100名患者中收集胸腔积液样本（8-10毫升），这些患者被分为三组：第1组（MPE，n = 56）、第2组（良性渗出液，n = 27）和第3组（漏出液，n = 17）。收集的积液立即在4°C下离心，上清液储存在-80°C。通过ELISA试剂盒（武汉优思晶生物）测定MCP-1水平。发现三组之间的MCP-1中位数水平有显著差异（第1组：1303 pg/ml，第2组：926 pg/ml，第3组：211 pg/ml）（<0.001）。与第3组相比，第1组和第2组的MCP-1水平明显更高但相似。当将第1组和第2组的患者合并时，观察到胸腔积液MCP-1与LDH水平之间存在正相关（r = 0.38； = 0.001）。此外，观察到MCP-1水平随着胸腔积液量的增加而显著升高（ = 0.007）。发现第1组（MPE）和第2组（良性渗出液）的MCP-1水平同样高，表明肿瘤伴随的炎症可能在胸腔积液的形成中起作用。这表明针对MCP-1的生物疗法的开发可能是未来MPE管理中有前景的方法。
